Central Nervous System Lymphoma — Trials

Central Nervous System Lymphoma — Trials · CancerIndex

Clinical trials

Registered studies

214 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 81
Recruiting: 54
Ph III recruiting: 5
Growth YoY: —
Industry share: 16%
Top sponsor: National Cancer Institute (NCI)
Termination share: 26.2%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (15)

clinicaltrialsPublishedShowing 1–6 of 6 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT07185373	Orelabrutinib Combined With Teniposide, Rituximab and Methotrexate for Newly Diagnosed PCNSL	recruiting	Phase 2 / Phase 3	215	Huashan HospitalOTHER	1	Aug 19, 2026	clinicaltrials
NCT04931368	OptiMATe: De-escalated Induction Treatment in Primary CNS Lymphoma(OptiMATe)	active not recruiting	Phase 3	331	Klinikum StuttgartOTHER	1	Mar 18, 2026	clinicaltrials